Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet all of the following criteria to be included in the Phase 1 portion of the study:~* Males and females between 18 and 64 years of age~* A negative urine pregnancy test and willingness to use a reliable form of contraception for the duration of the study (females of childbearing potential only), with reliable contraception defined as:~Abstinence Oral contraceptive, either estrogen progesterone combined, or progesterone alone Injectable progesterone Implants of levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patches Intrauterine device or intrauterine system Double barrier method \[condom or occlusive cap (diaphragm or cervical vault caps) plus spermicidal agent (foam, gel, film, cream, suppository)\] Male partner sterilization prior to the female subject's entry into the study, and this male is the sole partner for that subject~* Good health, as determined by pertinent medical history, physical examination, vital signs, and clinical safety laboratory evaluations~* A minimum of 16 natural teeth with 2 scorable surfaces (facial and lingual) per tooth Sufficient number of opposing posterior teeth to chew on both sides of the mouth as determined by the examining dentist Teeth that have gross caries, full crowns or extensive restorations on facial and/or lingual surfaces, orthodontic bands, and third molars are not included in the tooth count~* Ability to comprehend and a willingness to sign an informed consent, which includes the Authorization for the Release of Health Information document~* Willingness to comply with all study procedures~Phase 2a Inclusion Criteria~Subjects must meet all the criteria for the phase 1 portion of the study, and in addition must:~* Have mild to moderate gingivitis and plaque MGI of 1.8 or greater (Ainamo and Bay-1975) PI of 1.95 or greater (Turesky et al-1970)~* Willing to forgo any optional dental procedures during the study period, such as dental prophylaxis or teeth whitening~Exclusion Criteria:~Subjects meeting any of the following criteria will be excluded from the study:~* Acute or chronic medical conditions, organ system disease, or medications that, in the principal investigator's opinion, would impair the subject's ability to participate~* TMD~* Self-reported use of tobacco products~* Use of anticoagulant medications (eg clopidogrel)~* Gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or calculus, or soft or hard tissue tumor of the oral cavity~* Orthodontic appliances or removable partial dentures that will compromise the ability of the potential subject to participate in the study~* Periodontitis as indicated periodontal pockets greater than 4 millimeters on more than one site~* Receipt of any investigational drug/test product within 30 days prior to study entry~* Receipt of antibiotics within 30 days prior to study entry~* Need for antibiotic prophylaxis prior to invasive dental procedures~* Receipt of daily anti-inflammatory therapy \[eg nonsteroidal anti-inflammatory drugs (NSAID), tumor necrosis factor (TNF) alpha blockers\] within 30 days prior to study entry~* Receipt of prescription antibacterial oral products (eg products containing chlorhexidine) within 30 days prior to study entry~* Pregnant or breast-feeding female~* Clinically significant abnormal laboratory tests as determined by the principal investigator~* An employee of the study site directly involved with the study~* Inability to comply with assigned treatment regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- 2 mg KSL-W (Phase 1, 1a) (Type: EXPERIMENTAL): one 2 mg KSL-W tablet at day 0 at Phase 1
- 4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b) (Type: EXPERIMENTAL): one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
- 6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b) (Type: EXPERIMENTAL): One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
- 10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b) (Type: EXPERIMENTAL): One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
- 20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b) (Type: EXPERIMENTAL): One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
- 30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b) (Type: EXPERIMENTAL): One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
- 50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b) (Type: EXPERIMENTAL): One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
- 75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b) (Type: EXPERIMENTAL): One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
- 100 mg KSL-W (Phase 1, 9a) (Type: EXPERIMENTAL): one 100 mg KSL-W tablet at day 0 at Phase 1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).